Veslugen
A Khavinson-class kidney bioregulator. Marketed for renal function. As with the whole class, the evidence is Russian-language, unreplicated, and does not meet the standard applied elsewhere in this database.
Bioregulators
Vesilute
A Khavinson-class bladder bioregulator. Marketed for bladder function and urinary symptoms. As with the whole class, the evidence is Russian-language, unreplicated, and does not meet the standard applied elsewhere in this database.
Overview
Peptide bioregulators are built on a specific claim: that very short peptides extracted from — or synthesised to match — a particular organ can travel to that same organ and restore its normal function as it ages. Vesilute is the bladder version, promoted for urinary frequency, urgency and bladder function in ageing. The proposed route is direct interaction with DNA to switch tissue-specific genes back on. That mechanism has been demonstrated to the satisfaction of the group that proposed it and essentially nobody else.
A bladder-derived peptide preparation, reported by the originating group to influence urothelial function and detrusor tissue markers in animal models. No published human urodynamic data exists. The class hypothesis holds that di-, tri- and tetrapeptides penetrate cell and nuclear membranes and bind directly to specific promoter sequences in double-stranded DNA, modulating tissue-specific transcription — a mechanism supported by molecular modelling and gel-shift work from the originating institute but not independently corroborated. Products are marketed in two chemically distinct forms: "Cytomax" preparations, which are peptide fractions extracted from the corresponding animal organ, and "Cytogen" preparations, which are defined synthetic short peptides. Published clinical evaluation is limited to small Russian studies, generally without blinding, placebo control or independent statistical review.
Research areas
Bladder functionUrinary symptomsUrothelial biology
Dosing reported in the literature
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| 10 mg daily as an extract capsule, or 100–200 mcg daily for the synthetic peptide form, taken as a 10–30 day courseThis describes what is marketed, not a validated regimen. No dose-finding study has been published. | Russian supplier protocol |
Trial status
Small Russian studies from the originating institute. No registered Western trials, no independent replication, and no published randomised placebo-controlled evidence meeting international standards.
Reported safety signals
- Human safety data outside Russian clinical practice is effectively absent.
- No independent pharmacology, toxicology or clinical replication exists in the international literature.
- The "peptide bioregulator" gene-regulation hypothesis underlying this whole class comes from a single research group and is not independently established.
- Products sold under one name may be either an animal organ extract or a synthetic peptide — chemically different things with different risk profiles.
Common questions
Would this help overactive bladder?
Nothing published supports it. Overactive bladder has antimuscarinic and beta-3 agonist treatments with randomised trial evidence; urinary symptoms also warrant investigation rather than self-treatment, since they can signal obstruction, infection or malignancy.
Primary sources
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →